NCT06669533

Use Misoprostol to Optimize Prevention of Cervical Cancer

Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 420 (estimated)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: Female
• Age: 25 Years
• Healthy volunteers: Accepted

Summary

This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.

Conditions

• Cervical Cancers

Interventions

Type	Name	Description
DRUG	Placebo	Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).
DRUG	Misoprostol	Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

Timeline

• Start date: 2025-02-25
• Primary completion: 2026-11-04
• Completion: 2027-11-04
• First posted: 2024-11-01
• Last updated: 2025-10-01

Locations

1 site across 1 country: Cameroon